stonks4u
Sign up free
FATE logo

FATE Fate Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.57
+0.05 (+1.98%)

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute my…

Market Cap: $299.56Mwww.fatetherapeutics.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

50
5080110140
Aug 13Aug 14

Quote

Day Range
$2.48 – $2.60
52-Week Range
$0.93 – $3.23
Volume
$1.12M
Market Cap
$299.56M
50-Day Avg
$2.49
200-Day Avg
$1.62
Prev Close
$2.52
Open
$2.54

Valuation & Ratios

P/E Ratio
-0.85
EPS
$-1.15
P/B Ratio
0.56
P/S Ratio
17.56
Debt/Equity
0.38
Current Ratio
5.79
Dividend Yield
+0.0%
Gross Margin
-94.1%

Returns & Efficiency

Return on Equity
-65.8%
Return on Assets
-42.7%
FCF Yield
-96.0%
EV/EBITDA
-1.16

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$6.65M$-136.31M$-1.15
2024$13.63M$-186.26M$-1.64
2023$63.53M$-160.93M$-1.64
2022$96.30M$-281.72M$-2.91
2021$55.85M$-212.15M$-2.24

Social Signal Score

44
5d
45
3 mentions
—
30d
44
3 mentions
—
60d
44
3 mentions
—
90d
44
3 mentions
—
news: 3

Earnings

Thu, Nov 12(in 3 months)

Consensus estimate $-0.27 per share

7of 7 quarters beat consensus

Typical surprise +10.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.25 vs $-0.25beat
  • Wed, May 13$-0.26 vs $-0.29beat
  • Thu, Feb 26$-0.27 vs $-0.27beat
  • Thu, Nov 13$-0.27 vs $-0.29beat
  • Tue, Aug 12$-0.29 vs $-0.35beat
  • Tue, May 13$-0.32 vs $-0.39beat

Estimates and results for FATE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

FATEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsglobenewswire.com·1d ago·Neutral

    Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites

    View source ↗
  • Newszacks.com·2d ago·Negative

    Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.29 per share a year ago.

    View source ↗
  • Newsglobenewswire.com·2d ago·Neutral

    Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge

    View source ↗